Yıl: 2022 Cilt: 31 Sayı: 1 Sayfa Aralığı: 7 - 16 Metin Dili: İngilizce DOI: 10.5152/turkjnephrol.2022.21234 İndeks Tarihi: 07-07-2022

Recommendations for Kidney Patients in COVID-19 Era Based on Current Evidence

Öz:
Patients with chronic kidney disease, patients on dialysis, and kidney transplant recipients are at high risk of mortality and morbidity due to coronavirus disease-19. Most patients with chronic kidney disease are elderly and have other comorbidities. In addition, some of these patients have been exposed to immunosuppressive drugs to treat their underlying primary disease or to prevent allograft rejection. This general profile of chronic kidney disease patients renders them susceptible to a more severe course of coronavirus disease-19 once they are infected with severe acute respiratory syndrome coronavirus 2. Many studies showed that impaired kidney function on admission is an independent risk factor for a more severe course of coronavirus disease-19 with significantly increased risk for hospital and intensive care unit admission, intubation, mechanical ventilation, and death. Coronavirus disease-19 vaccination is crucial to create immunity in the general community, but the evidence addressing this specific population is scarce. However, based on the current evidence, all patients with chronic kidney disease are strongly recommended to receive the available vaccine in their country against coronavirus disease-19, and booster doses will presumably prove necessary for this group of patients. Furthermore, vigilant use of protective measures is strongly recommended for this patient population. Current studies and recommendations from health authorities should be followed closely.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Coronovirus: COVID live-coronovirus statistics-worldometer. Available at: https://www.worldmeters.info.
  • 2. ERA-EDTA Council, ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021;36(1):87-94. [CrossRef]
  • 3. De Lusignan S, Dorward J, Correa A, et al. Risk factors for SARSCoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020;20(9):1034-1042. (doi::[CrossRef])
  • 4. Williamson EJ, Walker AJ, Bhaskaran K, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature. 2020;584(7821):430-436. [CrossRef]
  • 5. Gibertoni D, Reno C, Rucci P, et al. COVID-19 incidence and mortality in non-dialysis chronic kidney disease patients. PLoS ONE. 2021;16(7):e0254525. [CrossRef]
  • 6. Uribarri A, Nuñez-Gil IJ, Aparisi A, et al. Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation forCOVID-19) registry. J Nephrol. 2020;33(4):737-745. [CrossRef]
  • 7. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-838. [CrossRef]
  • 8. Portolés J, Marques M, López-Sánchez PL, et al. Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak. Nephrol Dial Transplant. 2020;35(8):1353-1361. [CrossRef]
  • 9. Ji W, Huh K, Kang M, et al. Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: a nationwide casecontrol study. J Korean Med Sci. 2020;35(25):e237. [CrossRef]
  • 10. Fried MW, Crawford JM, Mospan AR, et al. Patient characteristics and outcomes of 11,721 patients with COVID19 hospitalized across the United States. Clin Infect Dis. 2021;72(10):e558-e565.
  • 11. Hernández-Galdamez DR, Gonzázlez-Block A, Romo-Dueñas DK, et al. Increased risk of hospitalization and death in patients with COVID-19 and pre-existing noncommunicable diseases and modifiable risk factors in Mexico. Arch Med Res. 2020;51(7):683-689. [CrossRef]
  • 12. Arikan H, Ozturk S, Tokgoz B, et al. Characteristics and outcomes of acute kidney injury in hospitalized COVID-19 patients: a multicenter study by the Turkish society of nephrology. PLoS ONE. 2021;16(8):e0256023. [CrossRef]
  • 13. Pavli A, Theodoridou M, Maltezou HC. Post-COVID syndrome: incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch Med Res. 2021;52(6):575-581. [CrossRef]
  • 14. Soler MJ, Jacobs-Cachá C. The COVID-19 pandemic: progress in nephrology. Nat Rev Nephrol. 2021;1-2. [CrossRef]
  • 15. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-232. [CrossRef]
  • 16. Hou YC, Lu KC, Kuo KL. The efficacy of COVID-19 vaccines in chronic kidney disease and kidney transplantation patients: a narrative review. Vaccines. 2021;9(8):885. [CrossRef]
  • 17. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensinaldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382(25):2441-2448. [CrossRef]
  • 18. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–angiotensin–aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382(25):2431-2440. [CrossRef]
  • 19. Ghosal S, Mukherjee JJ, Sinha B, Gangopadhyay KK. The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): a meta-analysis. medRxiv. 2020. [CrossRef]
  • 20. Soler MJ, Noordzij M, Abramowicz D,et al. Renin-angiotensin system blockers and the risk of COVID-19-Related mortality in patients with kidney failure. Clin J Am Soc Nephrol. 2021 July;16(7):1061- 1072. [CrossRef]
  • 21. Wysocki J, Ye M, Hassler L, et al. A novel soluble ACE2 variant with prolonged duration of action neutralizes SARS-CoV-2 infection in human kidney organoids. J Am Soc Nephrol. 2021;32:795-803. [CrossRef]
  • 22. Hassler L, et al. A novel soluble ACE2 protein totally protects from lethal disease caused by SARS- CoV-2 infection. bioRxiv [Preprint]. 2021 Mar. [CrossRef]
  • 23. Zoufaly A, Poglitsch M, Aberle JH, et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020;8(11):1154- 1158. [CrossRef]
  • 24. United States National Library of Medicine. 2021. Available at: https://clinicaltrials.gov/ct2/show/NCT04335136.
  • 25. Öztürk S, Gürsu M, Arıcı M, et al. COVID-19 Sonrası Periton Diyalizi Hastalarının Sonuçlarının Değerlendirilmesi: Ulusal Çok Merkezli Kontrollü Çalışma. In Turkish. 38th National Congress of Nephrology Hypertension Dialysis and Transplantation. Eleksus KKTC. 2021;2021:27-28.
  • 26. Ozturk S, Turgutalp K, Arici M, et al. Mortality analysis of COVID-19 in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. Nephrol Dial Transplant. 2020;35(12):2083-2095. [CrossRef]
  • 27. Jager KJ, Kramer A, Chesnaye NC, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020;98(6):1540-1548. [CrossRef]
  • 28. Fisher M, Yunes M, Mokrzycki MH, et al. Chronic hemodialysis patients hospitalized with COVID-19: short-term outcomes in the Bronx, New York. Kidney360. 2020;1(8):755-762. [CrossRef]
  • 29. Valeri AM, Robbins-Juarez SY, Stevens JS, et al. Presentation and outcomes of patients with ESKD and COVID-19. J Am Soc Nephrol. 2020;31(7):1409-1415. [CrossRef]
  • 30. Carfì A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603-605. [CrossRef]
  • 31. Mandal S, Barnett J, Brill SE, et al. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76(4):396- 398. [CrossRef]
  • 32. Writing Committee for the COMEBAC Study Group, Morin L, Savale L, et al. Four-month clinical status of a cohort of patients After hospitalization for COVID-19. JAMA. 2021;325(15):1525-1534. [CrossRef]
  • 33. Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2021;27(1):89-95. [CrossRef]
  • 34. Och A, Tylicki P, Polewska K, et al. Persistent post-COVID-19 syndrome in hemodialyzed patients-a longitudinal cohort study from the north of Poland. J Clin Med. 2021;10(19):4451. [CrossRef]
  • 35. Öztürk S, Turgutalp K, Arıcı M, et al. Türkiye’de Kronik Hemodiyaliz Hastalarında COVID-19 Uzun Dönem Sonuçları: Ulusal, Çok Merkezli Kontrollü Çalışma. In Turkish. 38th National Congress of Nephrology Hypertension Dialysis and Transplantation. SS-25. Eleksus KKTC. 2021;2021:25-26.
  • 36. Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19: a cross-sectional evaluation. J Med Virol. 2021;93(2):1013-1022. [CrossRef]
  • 37. Available at: https://covid19.saglik.gov.tr/TR-66532/saglik-kuru mlarinda-calisma-rehberi-ve-enfeksiyon-kontrol-onlemleri.html.
  • 38. Krammer F, Srivastava K, Alshammary H, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384(14):1372-1374. [CrossRef]
  • 39. Kliger AS, Silberzweig J. COVID-19 and dialysis patients: unsolved problems in early 2021. J Am Soc Nephrol. 2021;32(5):1018-1020. [CrossRef]
  • 40. Hill JB, Garcia D, Crowther M, et al. Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study. Blood Adv. 2020;4(21):5373-5377. [CrossRef]
  • 41. Menter T, Haslbauer JD, Nienhold R, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology. 2020;77(2):198-209. [CrossRef]
  • 42. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020;18(7):1559-1561. [CrossRef]
  • 43. Shabaka A, Gruss E, Landaluce-Triska E, et al. Late thrombotic complications after SARS-CoV-2 infection in hemodialysis patients. Hemodial Int. 2021;25(4):507-514. [CrossRef]
  • 44. Mitra S, Jayanti A, Vart P, et al. Clinical triage of patients on kidney replacement therapy presenting with COVID-19: an ERACODA registry analysis. Nephrol Dial Transplant. 2021;36(12):2308-2320. [CrossRef]
  • 45. Kingery JR, Bf Martin P, Baer BR, et al. Thirty-day post-discharge outcomes following COVID-19 infection. Journal of General Internal Medicine. 2021;36(8):2378-2385.
  • 46. Canney M, Er L, Antonsen J, et al. Maintaining the uptake of peritoneal dialysis during the COVID-19 pandemic: a research letter. Can J Kidney Health Dis. 2021;8:2054358120986265. [CrossRef]
  • 47. Wetmore J, JohansenK, LiuJ, et al. Changes in treatment of patients with incident end-stage kidney disease during the novel coronavirus disease 2019 pandemic. J Am Soc Nephrol. 2021;32(11): 2948-2957.
  • 48. Jiang HJ, Tang H, Xiong F, et al. COVID-19 in peritoneal dialysis patients. Clin J Am Soc Nephrol. 2020;16(1):121-123. [CrossRef]
  • 49. Hilbrands LB, Duivenvoorden R, Vart P, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant. 2020;35(11):1973- 1983. [CrossRef]
  • 50. Caillard S, Anglicheau D, Matignon M, et al. An initial report from the French Sot COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney Int. 2020;98(6):1549-1558. [CrossRef]
  • 51. Kates OS, Haydel BM, Florman SS, et al. COVID-19 in solid organ transplant: a multi-center cohort study. Clin Infect Dis. 2020.
  • 52. Azzi Y, Bartash R, Scalea J, Loarte-Campos P, Akalin E. COVID-19 and solid organ transplantation: a review article. Transplantation. 2021;105(1):37-55. [CrossRef]
  • 53. Goffin E, Candellier A, Vart P, et al. COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. Nephrol Dial Transplant. 2021;36(11):2094-2105. [CrossRef]
  • 54. Oto OA, Ozturk S, Turgutalp K, et al. Predicting the outcome of COVID-19 infection in kidney transplant recipients. BMC Nephrol. 2021;22(1):100. [CrossRef]
  • 55. Hilbrands LB, Duivenvoorden R, Vart P, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant. 2020;35(11):1973- 1983. [CrossRef]
  • 56. Loupy A, Aubert O, Reese PP, et al. Organ procurement and transplantation during the COVID-19 pandemic. Lancet. 2020;395(10237):e95-e96. [CrossRef]
  • 57. Suleymenlar G, Ates K, Seyahi N, Kocyigit I. Registry of the Nephrology, Dialysis and Transplantation in Turkey; 2020. Ankara: Türk Nefrolojı̇ Derneğı̇ Yayınları. 2021:123-132.
  • 58. Maggiore U, Abramowicz D, Crespo M, et al. How should I manage immunosuppression in a kidney transplant patient with COVID19? An ERA-EDTA Descartes expert opinion. Nephrol Dial Transplant. 2020;35(6):899-904. [CrossRef]
  • 59. American Society of Transplantation. nCoV (coronavirus): FAQs for organ donation and transplantation; 2019. Available at: https:// www.myast.org/sites/default/files/2021%200809%20COVID19%2 0FAQ.pdf.
  • 60. Akalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney transplantation. N Engl J Med. 2020;382(25):2475-2477. [CrossRef]
  • 61. Heldman MR, Kates OS, Safa K, et al. Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic. Am J Transplant. 2022;22(1):279- 288. [CrossRef]
  • 62. Hou Y-C, Lu K-C, Kuo K-L. The efficacy of COVID-19 vaccines in chronic kidney disease and kidney transplantation patients: a narrative review. Vaccines. 2021;9(8):885. [CrossRef]
  • 63. Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021;21(8):2719- 2726. [CrossRef]
  • 64. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant
  • recipients. JAMA. 2021;5:e217489. 65. Cucchiari D, Egri N, Bodro M, et al. Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant. 2021;21(8):2727-2739. [CrossRef]
  • 66. Malinis M, Cohen E, Azar MM. Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients. Am J Transplant. 2021;21(8):2916-2918. [CrossRef]
  • 67. Tsapepas D, Paget K, Mohan S, Cohen DJ, Husain SA. Clinically significant COVID-19 following SARS-CoV-2 vaccination in kidney transplant recipients. Am J Kidney Dis. 2021;78(2):314-317. [CrossRef]
  • 68. Eren Sadioğlu RE, Demir E, Evren E, et al. Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients. Transpl Infect Dis. 2021;23(6):e13740. [CrossRef]
  • 69. Kamar N, Abravanel F, Marion O, et al. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385(7):661-662. [CrossRef]
  • 70. Caillard S, Thaunat O. COVID-19 vaccination in kidney transplant recipients. Nat Rev Nephrol. 2021;17(12):785-787. [CrossRef]
  • 71. Giannella M, Pierrotti LC, Helanterä I, Manuel O. SARS-CoV-2 vaccination in solid-organ transplant recipients: what the clinician needs to know. Transpl Int. 2021;34(10):1776-1788. [CrossRef]
  • 72. Ou MT, Boyarsky BJ, Motter JD, et al. Safety and reactogenicity of 2 doses of SARS-CoV-2 vaccination in solid organ transplant recipients. Transplantation. 2021;105(10):2170-2174. [CrossRef]
  • 73. Stumpf J, Tonnus W, Paliege A, et al. Cellular and humoral immune responses after three doses of BNT162b2 mRNA SARS-Cov-2 vaccine in kidney transplant. Transplantation, 2021;105(11):e267 -e269. [CrossRef]
  • 74. Del Bello A, Marion O, Delas A, et al. Acute rejection after anti– SARS-CoV-2 mRNA vaccination in a patient who underwent a kidney transplant. Kidney Int. 2021;100(1):238-239. [CrossRef]
  • 75. Ducloux D, Courivaud C. Should vaccination against COVID-19 be mandated in patients on the transplant waiting list? Kidney Int. 2021;100(4):939-940. [CrossRef]
  • 76. Kant S, Kronbichler A, Salas A, Bruchfeld A, Geetha D. Timing of COVID-19 vaccine in the setting of anti-CD20 therapy: a primer for nephrologists. Kidney Int Rep. 2021;6(5):1197-1199. [CrossRef]
APA Ozturk S, Velioglu A, TUGLULAR Z (2022). Recommendations for Kidney Patients in COVID-19 Era Based on Current Evidence. , 7 - 16. 10.5152/turkjnephrol.2022.21234
Chicago Ozturk Savas,Velioglu Arzu,TUGLULAR ZÜBEYDE SERHAN Recommendations for Kidney Patients in COVID-19 Era Based on Current Evidence. (2022): 7 - 16. 10.5152/turkjnephrol.2022.21234
MLA Ozturk Savas,Velioglu Arzu,TUGLULAR ZÜBEYDE SERHAN Recommendations for Kidney Patients in COVID-19 Era Based on Current Evidence. , 2022, ss.7 - 16. 10.5152/turkjnephrol.2022.21234
AMA Ozturk S,Velioglu A,TUGLULAR Z Recommendations for Kidney Patients in COVID-19 Era Based on Current Evidence. . 2022; 7 - 16. 10.5152/turkjnephrol.2022.21234
Vancouver Ozturk S,Velioglu A,TUGLULAR Z Recommendations for Kidney Patients in COVID-19 Era Based on Current Evidence. . 2022; 7 - 16. 10.5152/turkjnephrol.2022.21234
IEEE Ozturk S,Velioglu A,TUGLULAR Z "Recommendations for Kidney Patients in COVID-19 Era Based on Current Evidence." , ss.7 - 16, 2022. 10.5152/turkjnephrol.2022.21234
ISNAD Ozturk, Savas vd. "Recommendations for Kidney Patients in COVID-19 Era Based on Current Evidence". (2022), 7-16. https://doi.org/10.5152/turkjnephrol.2022.21234
APA Ozturk S, Velioglu A, TUGLULAR Z (2022). Recommendations for Kidney Patients in COVID-19 Era Based on Current Evidence. Turkish journal of nephrology (Online), 31(1), 7 - 16. 10.5152/turkjnephrol.2022.21234
Chicago Ozturk Savas,Velioglu Arzu,TUGLULAR ZÜBEYDE SERHAN Recommendations for Kidney Patients in COVID-19 Era Based on Current Evidence. Turkish journal of nephrology (Online) 31, no.1 (2022): 7 - 16. 10.5152/turkjnephrol.2022.21234
MLA Ozturk Savas,Velioglu Arzu,TUGLULAR ZÜBEYDE SERHAN Recommendations for Kidney Patients in COVID-19 Era Based on Current Evidence. Turkish journal of nephrology (Online), vol.31, no.1, 2022, ss.7 - 16. 10.5152/turkjnephrol.2022.21234
AMA Ozturk S,Velioglu A,TUGLULAR Z Recommendations for Kidney Patients in COVID-19 Era Based on Current Evidence. Turkish journal of nephrology (Online). 2022; 31(1): 7 - 16. 10.5152/turkjnephrol.2022.21234
Vancouver Ozturk S,Velioglu A,TUGLULAR Z Recommendations for Kidney Patients in COVID-19 Era Based on Current Evidence. Turkish journal of nephrology (Online). 2022; 31(1): 7 - 16. 10.5152/turkjnephrol.2022.21234
IEEE Ozturk S,Velioglu A,TUGLULAR Z "Recommendations for Kidney Patients in COVID-19 Era Based on Current Evidence." Turkish journal of nephrology (Online), 31, ss.7 - 16, 2022. 10.5152/turkjnephrol.2022.21234
ISNAD Ozturk, Savas vd. "Recommendations for Kidney Patients in COVID-19 Era Based on Current Evidence". Turkish journal of nephrology (Online) 31/1 (2022), 7-16. https://doi.org/10.5152/turkjnephrol.2022.21234